Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Domenic A Sica Added: 3 years ago
Diabetes mellitus is rapidly increasing in its worldwide prevalence and is currently estimated to affect 7-8% of the US population.1 In 2005, 1.5 million new cases of diabetes were diagnosed in people aged 20 years or older in the US. In the not-so-distant past, type 2 diabetes mellitus was viewed as a seemingly benign condition, at least in the elderly, with little effect on life expectancy and… View more

Prevention & Chronic Conditions
Treatment of Hypertension in Patients with Chronic Kidney Disease
Author(s): Debbie L Cohen , Raymond R Townsend Added: 3 years ago
Chronic kidney disease (CKD) is increasingly prevalent, with an estimated 26 million adults with CKD in the US.1 Hypertension is the most common comorbidity in chronic kidney disease. At least 85% of patients with stage 3 CKD or greater have hypertension, making parenchymal kidney disease the most common ‘secondary’ form of hypertension. Treatment of hypertension can often be challenging, as… View more

Prevention & Chronic Conditions
IMPACT CKD: 10-year Outlook on CKD
Author(s): Jerome Rossert Added: 12 hours ago
Dr Jerome Rossert (Head of Clinical Renal, AstraZeneca) joins us to discuss the findings of IMPACT CKD, a modelling analysis study aiming to evaluate the potential impact of chronic kidney disease across the next 10 years.IMPACT CKD included eight countries, the United States, Brazil, the United Kingdom, Spain, Germany, the Netherlands, China and Australia. The findings of the study estimate that… View more

Prevention & Chronic Conditions
Radcliffe & CardioNerds @AHA22: EMPA-Kidney: Empagliflozin & CV Outcomes in Patients with Chronic Kidney Disease
Author(s): Kate Wilcox , David Preiss Added: 1 year ago
AHA 22 - Dr Kate Wilcox, CardioNerds Academic Fellow (Medical College of Wisconsin, US) joins us in this collaboration between the @CardioNerds and Radcliffe Cardiology to interview Dr David L Preiss(University of Oxford, UK), investigator of the late-breaking EMPA-Kidney trial (NCT03594110). The trial, first presented AHA 22, looked at the SGLT2i, empagliflozin's (Boehringer Ingelheim)effect on… View more

Heart Failure

Prevention & Chronic Conditions
Author(s): Karthiek R Narala , Thomas A LaLonde , Sohail Hassan , et al Added: 3 years ago
Chronic kidney disease (CKD) affects approximately 26 million people in the US.1 CKD is considered a coronary risk equivalent and also a risk factor for progression of cardiovascular disease (CVD).2 Cardiovascular death rates are 10–30 times higher in dialysis patients than in the general population.3 This increase in CKD patients is multifactorial and is now mainly considered via two pathways:… View more

Anticoagulation
Debasish Banerjee
Debasish Banerjee is a consultant nephrologist with special interest in cardiovascular complications of chronic kidney disease including heart failure, sudden cardiac death and cardiac workup before kidney transplantation in chronic kidney disease patients; glomerulonephritis, kidney stone disease and diabetic nephropathy. He serves as the Clinical Subdean for St Georges Hospital and Higher… View more
Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events
Author(s): Paul M Ridker Added: 2 years ago
Dr Paul Ridker (Brigham and Women’s Hospital, Boston, US) outlines the findings from a secondary analysis of the CANTOS trial, originally presented at ACC.22 (NCT01327846). CANTOS was a large multinational clinical trial that showed targeting inflammation with canakinumab significantly lowered major cardiovascular events. This secondary analysis was designed to evaluate the influence of lipids… View more

Prevention & Chronic Conditions
Job title: Professor of Medicine in the Division of Nephrology
Dr Navdeep Tangri is a Professor of Medicine in the Division of Nephrology at University of Manitoba, Winnipeg, CA.Dr Tangri's research programme is focused on the clinical management of patients with advanced chronic kidney disease. He developed the kidney failure risk equation (KFRE) to predict the need for dialysis in patients with chronic kidney disease. View more
Research Area(s) / Expertise: Job title: Assistant Professor of Medicine and Director of Clinical Hypertension Programs